JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sofuoglu, M.
Right arrow Articles by Takemori, A. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sofuoglu, M.
Right arrow Articles by Takemori, A. E.

Naloxone produces protracted tolerance in mice treated with a single dose of morphine

M Sofuoglu and AE Takemori

Department of Pharmacology, Medical School, University of Minnesota, Minneapolis.

Previously we have shown that naloxone (NLX)-induced withdrawal in acutely dependent mice [a single dose of 100 mg/kg of morphine sulfate (MS) s.c.] leads to an increase in the degree and duration of the dependent state. In this study we investigated the modulation of opioid tolerance by NLX in acutely tolerant mice (a single dose of 100 mg/kg of MS s.c.). When acutely tolerant mice were injected 3 hr later with 32 mg/kg of NLX, tolerance to the antinociceptive effect of MS could be observed for at least 12 days after MS injection. The same dose of NLX given 3 days after MS injection also led to the prolongation of MS tolerance whereas 4 mg/kg of NLX had no effect. By using the latter protocol, if the ineffective 4-mg/kg dose of NLX was preceded 2 hr before with 10 mg/kg of MS, tolerance to MS could be detected for at least 6 days. When this protracted tolerance (100 mg/kg of MS followed 3 hr later by 32 mg/kg of NLX) was studied at spinal and supraspinal sites, tolerance to MS at supraspinal sites was greater and more prolonged than at spinal sites. [D-Pen2,D-Pen5]enkephalin did not show cross-tolerance at either site. U50,488H [trans-(+/-)-3,4-dichloro-N- methyl-N-[2-(1- pyrrolidinyl)-cyclohexyl]benzeneacetamide) showed a slowly developing cross-tolerance only at the supraspinal sites. In acutely tolerant animals, the tolerance that developed at supraspinal and spinal sites was of equal magnitude and contributed additively to the total tolerance observed in the animals.(ABSTRACT TRUNCATED AT 250 WORDS)

Volume 254, Issue 3, pp. 836-840, 09/01/1990
Copyright © 1990 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 Physiol. GenomicsHome page
A. V. LOGUINOV, L. M. ANDERSON, G. J. CROSBY, and R. Y. YUKHANANOV
Gene expression following acute morphine administration
Physiol Genomics, August 28, 2001; 6(3): 169 - 181.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
I. Kissin, C. A. Bright, and E. L. Bradley Jr.
Acute Tolerance to Continuously Infused Alfentanil: The Role of Cholecystokinin and N-Methyl-D-Aspartate-Nitric Oxide Systems
Anesth. Analg., July 1, 2000; 91(1): 110 - 116.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1990 by the American Society for Pharmacology and Experimental Therapeutics.